{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:35:24Z","timestamp":1791272124680,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.autrev.2012.10.020","type":"journal-article","created":{"date-parts":[[2012,12,4]],"date-time":"2012-12-04T15:59:12Z","timestamp":1354636752000},"page":"575-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Different effects of biological drugs in rheumatoid arthritis"],"prefix":"10.1016","volume":"12","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Sall\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Boccassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.10.020_bb0005","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2012.10.020_bb0010","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.10.020_bb0015","doi-asserted-by":"crossref","first-page":"397-440","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2012.10.020_bb0020","first-page":"1204","article-title":"Anti-cytokine antibodies for rheumatic diseases","volume":"10","author":"Atzeni","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2012.10.020_bb0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2007.02.004","article-title":"What is the role of rituximab in the treatment of rheumatoid arthritis?","volume":"6","author":"Atzeni","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.10.020_bb0030","series-title":"Targeted therapies in rheumatology","first-page":"509","article-title":"Early arthritis","author":"Emery","year":"2003"},{"key":"10.1016\/j.autrev.2012.10.020_bb0035","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2012.10.020_bb0040","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2012.10.020_bb0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.autrev.2011.10.019","article-title":"Early treatment in early undifferentiated arthritis","volume":"11","author":"Olivieri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.10.020_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":"Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.10.020_bb0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2011.01.001","article-title":"Switching rheumatoid arthritis treatments: an update","volume":"10","author":"Atzeni","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2012.10.020_bb0060","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.autrev.2012.04.001","article-title":"The perioperative use of biologic agents in patients with rheumatoid arthritis","volume":"12","author":"Polachek","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.10.020_bb0065","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.dci.2011.03.031","article-title":"Origin and evolution of TNF and TNF receptor superfamilies","volume":"35","author":"Wiens","year":"2011","journal-title":"Dev Comp Immunol"},{"key":"10.1016\/j.autrev.2012.10.020_bb0070","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.18553\/jmcp.2011.17.s9-b.S14","article-title":"Biologic agents in rheumatoid arthritis: an update for managed care professionals","volume":"17","author":"Agarwal","year":"2011","journal-title":"J Manag Care Pharm"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.10.020_bb0075","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1478-6354-13-S1-S2","article-title":"Infliximab: 12 years of experience","volume":"13","author":"Smolen","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2012.10.020_bb0080","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/14740338.2011.581661","article-title":"Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"10","author":"Poddubnyy","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2012.10.020_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07853890.2010.549148","article-title":"Golimumab - a new tool in the armamentaria against inflammatory arthritis","volume":"43","author":"Ash","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.autrev.2012.10.020_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14712598.2012.645533","article-title":"Certolizumab pegol for the treatment of rheumatoid arthritis","volume":"12","author":"Horton","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2012.10.020_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/eci.12.6","article-title":"Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice","volume":"8","author":"Atzeni","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2012.10.020_bb0100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3899\/jrheum.100935","article-title":"Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better long term outcomes: post-hoc analysis of a randomized controlled trial","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2012.10.020_bb0105","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.21600","article-title":"Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2012.10.020_bb0110","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.10.020_bb0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIl-1ra), in patients with rheumatoid arthritis. A large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.10.020_bb0120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.10.020_bb0125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2011.10.005","article-title":"B-cell therapies in established rheumatoid arthritis","volume":"25","author":"Leandro","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2012.10.020_bb0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2012.10.020_bb0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/14740338.2011.562188","article-title":"The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis","volume":"10","author":"Brinkman","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2012.10.020_bb0145","first-page":"230","article-title":"T-cell agents in the treatment of rheumatoid arthritis - 2011 update","volume":"69","author":"Solomon","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0150","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0155","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ard.2007.085084","article-title":"Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial","volume":"67","author":"Genant","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","article-title":"Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor","volume":"49","author":"Dayer","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2012.10.020_bb0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/eci.10.2","article-title":"The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis","volume":"6","author":"Jones","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2012.10.020_bb0170","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [RADIATE study]","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0175","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: the LITHE study","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.10.020_bb0180","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0185","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/ard.2010.132134","article-title":"Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis","volume":"70","author":"Salliot","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.10.020_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/clpt.2011.278","article-title":"Biologics-based therapy for the treatment of rheumatoid arthritis","volume":"91","author":"Scott","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2012.10.020_bb0200","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2009.126714","article-title":"Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212002789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:20:04Z","timestamp":1643793604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212002789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1568997212002789"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.10.020","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different effects of biological drugs in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2012.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}